Objective:
Several anti-tubulin agents were introduced for the cancer treatment so far.
Despite successes in the treatment of cancer, these agents cause toxic side effects, including peripheral
neuropathy. Comparing anti-tubulin agents, indibulin seemed to cause minimal peripheral
neuropathy, but its poor aqueous solubility and other potential clinical problems have led to its remaining
in a preclinical stage.
Methods:
Herein, indibulin analogues were synthesized and evaluated for their in vitro anti-cancer
activity using MTT assay (on the MCF-7, T47-D, MDA-MB231 and NIH-3T3 cell lines), annexin
V/PI staining assay, cell cycle analysis, anti-tubulin assay and caspase 3/7 activation assay.
Results:
One of the compounds, 4a, showed good anti-proliferative activity against MCF-7 cells
(IC50: 7.5 μM) and low toxicity on a normal cell line (IC50 > 100 μM). All of the tested compounds
showed lower cytotoxicity on normal cell line in comparison to reference compound, indibulin. In
the annexin V/PI staining assay, induction of apoptosis in the MCF-7 cell line was observed. Cell
cycle analysis illustrated an increasing proportion of cells in the sub-G-1 phase, consistent with an
increasing proportion of apoptotic cells. No increase in G2/M cells was observed, consistent with
the absence of anti-tubulin activity. A caspase 3/7 assay protocol showed that apoptosis induction
by more potent compounds was due to activation of caspase 3.
Conclusion:
Newly synthesized compounds exerted acceptable anticancer activity and further investigation
of current scaffold would be beneficial.
Anti cancer activity of Trachyspermum ammi against MCF7 cell lines mediates by p53 and Bcl-2 mRNA levels
